ReviewhLife2023
Fecal microbiota transplantation: A new strategy to delay aging.
Review in hLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota, the community of gut microorganisms that inhabit the gastrointestinal tract, plays a crucial role in modulating host immunity, metabolism, and neurological health, thereby influencing the entire organism. Aging is associated with changes in gut microbiota composition and functionality, often resulting in dysbiosis, an imbalance of gut microbiota and an aging hallmark. Recent studies have suggested that fecal microbiota transplantation (FMT), the transfer of fecal material containing beneficial microbes from a healthy donor to a recipient with a disturbed microbiota, may restore the balance of host gut microbiota and ameliorate some aging-associated impairments in diverse organs. In particular, FMT from young donors has shown more beneficial effects than FMT from aged donors. In this paper, we review recent advances in FMT for its effects on aging and discuss the potential mechanisms and challenges of this novel intervention, highlighting its potential to improve health outcomes in the aging population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.